MAP2K7 and acral lentiginous melanoma: In the relatively infrequent cases of ALM harboring BRAF mutations, the level of response to BRAF and BRAF-MEK inhibition is similar to BRAF-mutant non-ALM cutaneous melanoma, although the length of response tends to be shorter for ALM than non-ALM cutaneous melanoma (8).